81218 Cebpa gene full sequence
Also known as: CEBPA sequencing, CEBPA full analysis
Complete sequence analysis of the CEBPA gene to identify mutations associated with acute myeloid leukemia.
In Plain Language
acute leukemia gene test; blood cancer genetic screening
Clinical Context
Used to identify CEBPA mutations in acute myeloid leukemia for prognostic assessment and risk stratification.
RVU Information
CPT 81218 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 81218?
CPT 81218 (Cebpa gene full sequence) is a Pathology & Lab code. Complete sequence analysis of the CEBPA gene to identify mutations associated with acute myeloid leukemia.
Who uses CPT code 81218?
CPT 81218 is used by Hematology, Oncology, Pathology. Used to identify CEBPA mutations in acute myeloid leukemia for prognostic assessment and risk stratification.
When is CPT 81218 used?
Used to identify CEBPA mutations in acute myeloid leukemia for prognostic assessment and risk stratification.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.